

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Microsoft Teams
Meeting ID: 282 394 761 021
Password: 7frMSt

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT bochoa@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: [Microsoft Teams Meeting](#) OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: +1 510-210-0967,734845280#. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC](#).

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i>	
	<ul style="list-style-type: none"> End of public health emergency – meeting in person Conflict of Interest Check/Disclosure Agenda Overview 	2 min -
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	
	<ul style="list-style-type: none"> CalAIM Update (ECM, CS, LTC) Mental Health insourcing Chief of Health Equity Officer CEO transition Single plan county 2024 Medicare DHCS audit Medi-Cal Rx MCDAC Drugs (See Next Page) 	15 min -

MCDAC Drug	Indication	CDL Status	Recommendation Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Carbaglu (carglumic acid) 100mg tablets	Acute & Chronic Hyperammonemia	F-PA	Keep F-PA	NF
Carospir (spironolactone) 25mg/5ml oral suspension	CHF, HTN and Edema caused by cirrhosis	F	Keep F	NF
Norliqva (amlodipine) 1mg/ml oral solution	Hypertension for 6 years old and up	F	Keep F	NF
Pheburane (sodium phenylbutyrate) 48.3mg/g pellets	Urea cycle disorder (adjunct)	F-PA	Keep F-PA	NF
Sotyktu (deucravacitinib) 6mg tablets	Plaque Psoriasis	F-PA	Keep F-PA	NF
Tadliq (tadalafil) 20mg/5ml oral solution	Pulmonary Arterial Hypertension	F-PA	Keep F-PA	F-PA

III) Pharmacy Utilization Reports (Quarter 4, 2022)

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

- Top 50 Drugs by Cost
- Top 50 PA Reviewed Drugs

2 min

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

Estimated Date of Public Disclosure: 3/28/2023 (formulary changes only; no trade secrets will be disclosed)

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Helen Lee, PharmD, Pharmacist, Alameda Alliance

Benita Ochoa, CPhT, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Direct oral anticoagulants	• No change
Methergine monograph	• No change
Medication Request Guidelines	Changes
Angiotensin II Receptor Blockers and Renin Inhibitors	• Minor spelling updates
Brilinta (ticagrelor) tablet	• Update ABCD2 scores in coverage duration to align with the review criteria
Antifibrotic Respiratory Tract Agents	• Remove duplicative statements • Minor verbiage adjustments
Cystic Fibrosis Agents	• Minor verbiage adjustments
Agents for Atopic Dermatitis	• Minor spelling updates
Synagis	• Minor spelling updates
Symlin	• No change
Histamine H2 Receptor Antagonists	• No change

10 min **EV**

Elmiron (pentosane polysulfate sodium)	• No change
Ezetimibe (Zetia)	• No change
Antibiotic Eye Medications	• No change
Atovaquone (Mepron)	• No change
Tadalafil (Cialis) for BPH	• No change
Altoprev (lovastatin ER) and Fluvastatin, Fluvastatin ER	• No change
Linezolid	• No change
Pyridostigmine (Mestinon)	• No change
Thrombocytopenia Agents	• No change
Corticosteroid Preparations to Treat Hemorrhoids	• No change
Diuretics	• No change
Savella (milnacipran) tablet	• No change
Travoprost (Travatan Z) ophthalmic drops	• No change
Arikayce (amikacin)	• No change
Physician Administered Drug (PAD) Guidelines	Changes
Emergency Use Authorization (EUA) Drugs/Products for COVID-19	• No change
Ophthalmic indications for bevacizumab	• No change
Immunoglobulin Therapy (IVIG)	• No change
Interim Formulary Updates	
• See p. 87 in packet	
Pharmacy Policy & Procedure Updates	
• RX – 001 Pharmaceutical Operating Processes Summary	• No change
• RX – 002 PA Review Process	• UM alignment with 90-day PA retro lookback
• RX – 003 Exception Review Process	• Partial fill • Member reimbursement • External review
• RX – 004 Formulary Management	• Iatrogenic infertility coverage inclusion • Copayments lower than retail price requirement • Antiretroviral and PrEP access w/o auth
• RX – 005 P&T Committee Roles and Scope	• No change
• RX – 006 Pharmacy Services Staff Description	• No change

• RX – 007 Pharmaceutical Patient Safety	• No change
• RX – 008 PBM Delegated Audit Oversight	• No change
• RX – 009 Emergency Supply Provision	• No change
• RX – 010 Drug Utilization Management	• Anti-psychotic, Mood stabilizer and Anti-depressant monitoring per DMHC APL 22-031
• RX – 011 Decision and Notification Requirements	• No change
• RX – 012 DU Policies – Pharmacy Portal UD Access	• No change
ED Oversight	
• No updates	
90 Day Maintenance List updates	
• Add Spiriva HandiHaler	
P&T Meeting Minutes	
• P&T Meeting Minutes Q4 December 20, 2022	

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Reblozyl (luspatercept-aamt) PAD – new
- Formulary benchmark recommendations for addition

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Tziold monograph + new PAD
2. Rebyota monograph + new PAD
3. Agents for Sickle Cell disease + new MRG
4. Mounjaro monograph
5. Second generation antihistamines
6. Inhaled anticholinergics
7. Calcium channel blockers
8. Pulmonary arterial hypertension

45 min **V**

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

1. Corlanor (ivabradine)
2. Low Molecular Weight Heparins
3. Estrogen Patches and Injectables
4. Parkinson’s Disease Agents
5. Specialty Biological Agents Preferred Products
6. Specialty Biological Agents for Crohn’s Disease
7. Specialty Biological Agents for Ulcerative Colitis
8. Specialty Biological Agents for Rheumatoid Arthritis
9. Specialty Biological Agents for Adult Psoriatic Arthritis (PsA)
10. Specialty Biological Agents for Psoriasis
11. Specialty Biological Agents for Juvenile Idiopathic Arthritis

12. Specialty Biological Agents for Ankylosing Spondylitis
13. Specialty Biological Agents for Nonradiographic Axial Spondyloarthritis (nr-axSpA)
14. Specialty Biological Agents for Hidradenitis Suppurativa
15. Specialty Biological Agents for Giant Cell Arteritis
16. Specialty Biological Agents for Uveitis
17. PCSK-9 Inhibitors
18. Xolair (omalizumab) for Asthma and Urticaria
19. Antihypertensives
20. Verquvo

VIII) Physician Administered Drug (PAD) Policies

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Anti-CD20 Monoclonal Antibodies (mAb)
2. Specialty Biological Agents for Juvenile Idiopathic Arthritis
3. Specialty Biological Agents for Hidradenitis Suppurativa
4. Specialty Biological Agents for Giant Cell Arteritis
5. Specialty Biological Agents for Uveitis
6. Specialty Biological Agents for Crohn’s Disease
7. Specialty Biological Agents for Ulcerative Colitis
8. Specialty Biological Agents for Rheumatoid Arthritis
9. Specialty Biological Agents for Adult Psoriatic Arthritis (PsA)
10. Specialty Biological Agents for Psoriasis
11. Specialty Biological Agents for Ankylosing Spondylitis
12. Specialty Biological Agents for Nonradiographic Axial Spondyloarthritis (nr-axSpA)
13. Oxlumo (lumasiran)

10 min V

IX) Informational Updates on New Developments in Pharmacy

2 min

Natalee Felten, PharmD, Pharmacist, PerformRx

- New Product Review

X) Old Business

2 min

Natalee Felten, PharmD, Pharmacist, PerformRx

- Hemgenix monograph + new PAD (previously voted on by proxy)

RECONVENE IN OPEN SESSION

XI) Public Comment

XII) Adjournment

- P&T Committee Member Forms

ACTION / FOLLOW-UP ITEMS		
ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2023 P&T MEETINGS
June 20, 2023	September 26, 2023
	December 19, 2023

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.